文献速递皮肤感染

外用一氧化氮释放型贝尔达齐默凝胶治疗传染性软疣的疗效与安全性:一项3期随机临床试验

Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2022-01-01

多中心、赋形剂对照、双盲3期随机临床试验(B-SIMPLE4)在美国55家诊所纳入891例6月龄及以上、有3至70个隆起性传染性软疣皮损的患者,随机接受贝尔达齐默凝胶10.3%或赋形剂凝胶每日1次外用12周。第12周贝尔达齐默组完全清除率32.4%(144例) vs 赋形剂组19.7%(88例),绝对差12.7%,OR 2.0(95%CI 1.5-2.8),P<.001;不良事件率低,最常见为用药部位疼痛和红斑,多为轻度。

要点

  • 贝尔达齐默凝胶10.3%每日1次外用12周,第12周完全清除率32.4% vs 赋形剂19.7%。
  • 组间绝对差12.7%,OR 2.0(95%CI 1.5-2.8),P<.001。
  • 不良事件率低,最常见为用药部位疼痛和红斑,多为轻度。

核心结论

  • 贝尔达齐默凝胶10.3%用于传染性软疣似乎显示出良好的疗效和安全性,不良事件率低。

研究设计与样本

  • 多中心、赋形剂对照、双盲3期随机临床试验(B-SIMPLE4),于2020年9月1日至2021年7月21日在美国55家诊所(多为皮肤科和儿科)开展。
  • 纳入6月龄及以上、有3至70个隆起性传染性软疣皮损的患者,排除性传播传染性软疣或仅眶周区域有传染性软疣者。
  • 共891例参与者随机分组,贝尔达齐默凝胶10.3%组444例(平均[范围]年龄6.6[0.9-47.5]岁;男性228例[51.4%];白人387例[87.2%]),赋形剂组447例(平均[范围]年龄6.5[1.3-49.0]岁;女性234例[52.3%];白人382例[85.5%])。
  • 患者随机接受贝尔达齐默凝胶10.3%或赋形剂凝胶,薄层涂于所有皮损,每日1次,共12周。

主要发现

  • 意向治疗人群中,贝尔达齐默组88.5%(393例)和赋形剂组88.8%(397例)在第12周进行了皮损计数。
  • 第12周贝尔达齐默组32.4%(144例)达到所有传染性软疣皮损完全清除,赋形剂组为19.7%(88例)(绝对差12.7%;OR 2.0;95%CI 1.5-2.8;P<.001)。
  • 因传染性软疣清除而停止治疗者贝尔达齐默组为14.4%(64例),赋形剂组为8.9%(40例)。
  • 导致停药的不良事件影响贝尔达齐默组4.1%(18例)和赋形剂组0.7%(3例)。
  • 最常见不良事件为用药部位疼痛和红斑,多为轻度;最常见的局部皮肤反应为轻至中度红斑。

关键数值与推荐

  • 主要疗效终点为第12周所有传染性软疣皮损完全清除。
  • 第12周完全清除率贝尔达齐默组32.4%(144例) vs 赋形剂组19.7%(88例),绝对差12.7%,OR 2.0(95%CI 1.5-2.8),P<.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Molluscum contagiosum (MC) is a highly contagious skin condition. Lesions may persist for months to years, and no US Food and Drug Administration-approved medications are currently available in the US. OBJECTIVE: To assess the efficacy and safety of berdazimer gel, 10.3%, a novel topical nitric oxide-releasing medication, in the treatment of MC. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, vehicle-controlled, double-blind, phase 3 randomized clinical trial (B-SIMPLE4) conducted in 55 clinics (mostly dermatology and pediatric) in the US from September 1, 2020, to July 21, 2021. Eligible participants were 6 months or older and had from 3 to 70 raised MC lesions. Patients with sexually transmitted MC or with MC only in the periocular area were excluded. INTERVENTIONS: Patients were randomized to treatment with berdazimer gel, 10.3%, or vehicle gel, applied as a thin layer to all lesions once daily for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was complete clearance of all MC lesions at week 12. Safety and tolerability measures included adverse event frequency and severity, and assessment of local skin reactions and scarring. Data analyses were performed from August 31, 2021, to September 14, 2021. RESULTS: A total of 891 participants were randomized, 444 to berdazimer, 10.3% (mean [range] age, 6.6 [0.9-47.5] years; 228 [51.4%] male; 387 [87.2%] White individuals), and 447 to vehicle (mean [range] age, 6.5 [1.3-49.0] years; 234 [52.3%] female; 382 [85.5%] White individuals). In the intention-to-treat population, 88.5% (393 patients) in the berdazimer group and 88.8% (397 patients) in the vehicle group had a lesion count performed at week 12. At week 12, 32.4% (144 patients) in the berdazimer group achieved complete clearance of MC lesions compared with 19.7% (88 patients) in the vehicle group (absolute difference, 12.7%; odds ratio, 2.0; 95% CI, 1.5-2.8; P < .001) with 14.4% (64 patients) of the berdazimer group discontinuing treatment because of MC clearance compared with 8.9% (40 patients) of the vehicle group. Adverse event rates were low. The most common adverse events were application-site pain and erythema, mostly mild in severity. Adverse events leading to discontinuation affected 4.1% (18 patients) of the berdazimer group and 0.7% (3 patients) of the vehicle group. The most common local skin reaction was mild to moderate erythema. CONCLUSIONS AND RELEVANCE: Use of berdazimer gel, 10.3%, for MC appears to demonstrate favorable efficacy and safety with low adverse event rates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04535531.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Browning JC, Enloe C, Cartwright M, et al. Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022. PMID: 35830173. doi:10.1001/jamadermatol.2022.2721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。